Marketing Approval, Quarterly Reports, and Donation - Research Report on Allergan, Forest, Cubist, Sanofi, and The Medicines Company
NEW YORK, November 1, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Allergan Inc. (NYSE: AGN), Forest Laboratories Inc. (NYSE: FRX), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Sanofi (NYSE: SNY), and The Medicines Company (NASDAQ: MDCO). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Allergan Inc. Research Report
On October 23, 2013, Allergan Inc. (Allergan) announced that the US Food and Drug Administration has given its approval to market JUVÉDERM VOLUMA XC, the first and only filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21. Scott M. Whitcup, M.D., Executive Vice President, Research and Development, Chief Scientific Officer, Allergan, stated, "We are pleased that the FDA has now approved JUVÉDERM VOLUMA XC, the first product of its kind specifically formulated to correct age-related volume loss in the cheek area. JUVÉDERM VOLUMA XC represents the latest innovation in Allergan's growing portfolio of facial aesthetic products developed to address previously unmet patient needs." The Full Research Report on Allergan Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/182a_AGN]
Forest Laboratories Inc. Research Report
On October 22, 2013, Forest Laboratories Inc. (Forest) released its Q2 FY 2014 results (period ended September 30, 2013). Forest registered net revenues of $855.3 million in Q2 FY 2014, up 12.4% YoY. The Company posted net income of $70.0 million in Q2 FY 2014, up 236.8% YoY. Forest reported diluted EPS of $0.26, up compared to $0.08 in Q2 FY 2013. Commenting on the results, Brent Saunders, CEO and President of Forest, said, "There is rejuvenation underway at Forest as we return to growth. We have a motivated and talented workforce, we are launching new products and we are developing new drugs to drive future growth. This quarter sales increased 17% and non-GAAP earnings per share more than doubled." Saunders continued, "To make Forest more relevant to all of our key stakeholders - customers & patients; owners; partners and colleagues - we are conducting a thorough review of our business operations and evaluating changes to our strategy." The Full Research Report on Forest Laboratories Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/ea24_FRX]
Cubist Pharmaceuticals Inc. Research Report
On October 22, 2013, Cubist Pharmaceuticals Inc. (Cubist) released its Q3 2013 results. Cubist registered total net revenues of $266.0 million in Q3 2013, up 11.7% YoY. The Company posted net loss of $33.9 million in Q3 2013, compared to net income of $40.3 million in Q3 2012. Cubist further reported diluted loss per share of $0.50 in Q3 2013, compared to diluted EPS of $0.55 in Q3 2012. Michael Bonney, CEO of Cubist, stated, "This was an exciting quarter for Cubist as we extended our global leadership in the acute care environment and took a major step towards achieving our Building Blocks of Growth strategic goals. We believe our transactions to acquire Trius and Optimer will enhance our product portfolio and position us to further leverage our differentiated business model with our promising pipeline candidates." Bonney added, "We look forward to another important quarter ahead that we expect will include top-line data readouts from the cUTI and cIAI trials of our Phase 3 candidate ceftolozane/tazobactam." The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/92f2_CBST]
Sanofi Research Report
On October 21, 2013, Sanofireported that it has signed agreements to donate €2 million to support the first two academic chairs of the new French-German Centre Virchow-Villermé for Public Health, in commemoration of the 50th anniversary of the Elysée Treaty. Christopher A. Viehbacher, CEO of Sanofi, commented, "In the 50th year of the Elysée Treaty, the donation of these first two Chairs further supports the intensive collaboration between our two countries in the field of science, politics and the economy." Viehbacher concluded, "It is only through partnership that we can succeed and through these chairs, we are bringing together actors in education, research, science and industry to make a real difference in promoting health and well-being." The Full Research Report on Sanofi - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/29ea_SNY]
The Medicines Company Research Report
On October 23, 2013, The Medicines Company released its Q3 2013 results. The Medicines Company registered net revenue of $174.3 million in Q3 2013, up 27.4% YoY. Net income attributable to the Company was $7.8 million in Q3 2013, compared to $9.3 million in Q3 2012. The Company reported diluted EPS of $0.12 in Q3 2013, compared to diluted EPS of $0.17 in Q3 2012. Glenn Sblendorio, President and Chief Financial Officer of The Medicines Company, stated, "The third quarter was yet another financial growth period and we made significant progress with our acute/intensive care portfolio." Sblendorio continued, "We continue to make progress on our late stage development programs with four product launches anticipated in the next 12 to 24 months. We are serving a concentrated, yet growing worldwide hospital market while leveraging and building our organization efficiently, consistent with our purpose to save lives, alleviate suffering, and contribute to the economics of healthcare by focusing on leading hospitals worldwide." The Full Research Report on The Medicines Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/5a84_MDCO]
EDITOR NOTES:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner
Share this article